Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 1 country.
Huimin ZhangDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0003-0895-5920
Yuwei ZhangDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Jun PanDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Qielan WuDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0003-3062-9195
Yuanyuan HuangDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Shiyu BaiDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Chenxi TianDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Mingzhao ZhuKey Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.ORCID 0000-0003-2001-2669
Zhexiong LianInstitutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou 510006, China.
Fengyin LiHefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0003-4881-3281
Zhigang TianHefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0002-5512-6378
Li BaiDepartment of Oncology of the First Affiliated Hospital, Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China; baili@ustc.edu.cn.ORCID 0000-0002-9028-1920
University of Science and Technology of China · CNChinese Academy of Sciences · CNSouth China University of Technology · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Invariant natural killer T (iNKT) cells play important roles in regulating immune responses. Based on cytokine profiling and key transcriptional factors, iNKT cells are classified into iNKT1, iNKT2, and iNKT17 subsets. However, whether the development and functions of these subsets are controlled by distinct mechanisms remains unclear. Here, we show that forkhead box protein O1 (Foxo1) promotes differentiation of iNKT1 and iNKT2 cells but not iNKT17 cells because of its distinct contributions to IL7R expression in these subsets. Nuclear Foxo1 is essential for
Indexed as
AnimalsCell DifferentiationForkhead Box Protein O1Interleukin-7 Receptor alpha SubunitMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLNatural Killer T-CellsNuclear Receptor Subfamily 1, Group F, Member 3Signal TransductionTranscription FactorsForkhead Box Protein O1Foxo1 protein, mouseInterleukin-7 Receptor alpha SubunitMechanistic Target of Rapamycin Complex 1Nuclear Receptor Subfamily 1, Group F, Member 3Transcription FactorsdevelopmentFoxo1functioniNKT subsetsTSC2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
iNKT subsets differ in their developmental and functional requirements on Foxo1. · full record | OpenQuestion